Cargando…
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
AIMS: To evaluate potential differences between PF‐05280586 and rituximab sourced from the European Union (rituximab‐EU) and USA (rituximab‐US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity...
Autores principales: | Williams, Jason H., Hutmacher, Matthew M., Zierhut, Matthew L., Becker, Jean‐Claude, Gumbiner, Barry, Spencer‐Green, George, Melia, Lisa A., Liao, Kai‐Hsin, Suster, Matthew, Yin, Donghua, Li, Ruifeng, Meng, Xu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099556/ https://www.ncbi.nlm.nih.gov/pubmed/27530379 http://dx.doi.org/10.1111/bcp.13094 |
Ejemplares similares
-
A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2016) -
Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017) -
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
por: Feng, Yan, et al.
Publicado: (2014) -
Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
por: Allen, Ann, et al.
Publicado: (2014) -
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)